Pars plana vitrectomy with ranibizumab as adjuvant for patients with proliferative diabetic retinopathy
Objective To observe the effect of pars plana vitrectomy(PPV)with intravitreal injection of ranibizumab injection as adjuvant for patients with proliferative diabetic retinopathy(PDR)and its influence on surgical complications.Methods Forty-five patients with PDR(45 eyes)treated in Jilin Provincial People's Hospital from June 2022 to October 2023 were selected as the study objects.The patients were divided into a control group(24 cases and 24 eyes)and an experimental group(21 cases and 21 eyes)according to the different treatment methods.There were 17 males and 7 females in the control group;they were(57.46±9.14)years old;their disease course was(8.08±4.75)years.There were 11 males and 10 females in the experimental group;they were(52.09±10.20)years old;their disease course was(10.00±3.61)years.The control group took PPV;in addition,the experimental group were intraocularly injected 0.05 ml ranibizumab injection one week before the surgery.The basic data,operation times,intraoperative data(incidences of iatrogenic hole,using electrocoagulation,intraocular filling with inert gas and silicone oil,and signifiicant intraoperative bleeding),and incidences of surgical complications were compared between the two groups.The best corrected visual acuities(BCVA)before and 1 and 3 months after the surgery were evaluated.t and x2 tests were applied.Results There were no statistical differences in the basic data between the two groups(all P＞0.05).The operation time and incidences of iatrogenic hole,using electrocoagulation,intraocular filling with inert gas and silicone oil,and significant intraoperative bleeding in the experimental group were lower than those in the control group[(51.00±5.65)minvs.(71.29±6.19)min,9.52％(2/21)vs.45.83％(11/24),4.76％(1/21)vs.41.67％(10/24),14.29％(3/21)vs.50.00％(12/24),and 4.76％(1/21)vs.33.33％(8/24)],with statistical differences(t=11.426;x2=5.529,6.382,4.922,and 4.068;all P＜0.05).There were no statistical differences in the BCVA before and 1 and 3 months after the surgery between the two groups(all P＞0.05).The BCVA 1 and 3 months after the surgery were lower than those before the surgery in both groups,with statistical differences(t=7.656,9.603,5.090,and 10.325;all P＜0.05).The patients were followed up for 3 months;there were no statistical differences in the early hemorrhage(≤1 month)and total incidence of complications(both P＞0.05),but was in late hemorrhage(＞1 month)(t=4.564;P＜0.05)between the two groups.Conclusions Intravitreal injection of ranibizumab can reduce the incidence of complications during PPV for patients with PDR,shorten the operation time,and improve their BCVA after surgery.
Proliferative diabetic retinopathyRanibizumabPars plana vitrectomy
万方数据
维普
